Cell Biochem Biophys (2015) 71:105–112 DOI 10.1007/s12013-014-0168-1
ORIGINAL PAPER
EZH2-Induced H3K27me3 is Associated with Epigenetic Repression of the ARHI Tumor-Suppressor Gene in Ovarian Cancer Yibing Fu • Jing Chen • Bo Pang • Chunyan Li Jing Zhao • Keng Shen
•
Published online: 31 July 2014 Ó Springer Science+Business Media New York 2014
Abstract Epithelial ovarian cancer (EOC) is the second leading cause of death from gynecological malignancies worldwide. Enhancer of zeste homology 2 (EZH2), participating in gene expression silencing by trimethylating histone 3 lysine 27 (H3K27me3), is often up-regulated in EOC. ARHI, an imprinted tumor-suppressor gene, is markedly down-regulated or even undetectable in the majority of EOC. To explore the correlation between EZH2 and ARHI expression in EOC as well as the possible mechanism of EZH2–ARH1 interaction. We used immunohistochemical staining to evaluate the expression of EZH2 and ARHI in EOC and normal ovarian tissue specimens; western blotting, shRNA, and chromatin immunoprecipitation were used to study the expression correlation of EZH2 and ARHI in EOC and normal ovarian epithelial cells and to further explore the mechanism of EZH2 regulation of ARHI expression. Cell viability assay was used to evaluate the influence of these two genes on cell survival. (1) The expression of EZH2 inversely correlated with ARHI expression levels and Electronic Supplementary Material The online version of this article (doi:10.1007/s12013-014-0168-1) contains supplementary material, which is available to authorized users. Y. Fu K. Shen (&) Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China e-mail: [email protected] Y. Fu J. Chen C. Li J. Zhao Department of Gynecology and Obstetrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China B. Pang Department of Neurosurgery, Qilu Hospital, Shandong University, 107# Wenhuaxi Rd, Jinan 250012, China
predicted shorter overall survival in EOC patients; (2) EZH2 promoted repression of ARHI by catalyzing trimethylation on H3K27; (3) ARHI was synergistically silenced by DNA methylation and histone modification; and (4) DZNep, an inhibitor of EZH2, significantly reduced survival rate of EOC cells by restoring ARHI expression. EZH2-00 induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in EOC. Suppression of EZH2 by DZNep, as a way of restoring the expression of ARHI, could be a potential treatment modality to EOC. Keywords EZH2 H3K27me3 Epigenetic repression of the ARHI tumor-suppressor gene
Introduction Epithelial ovarian cancer (EOC) is the seventh most common cancer in women and the second leading cause of death from gynecological malignancies worldwide [1]. There is an urgent need, therefore, for better understanding of the etiology of EOC in order to develop novel therapeutics for this disease. Enhancer of zeste homology 2 (EZH2) is an essential catalytic subunit of polycomb repressive complex 2 (PRC2), which silences gene expression by generating a methylated epigenetic mark at the lysine 27 residue of histone H3 (H3K27me3) [2]. Previous studies showed that EZH2 is often up-regulated in EOC and in ovarian cancer-associated stromal endothelial cells. Enhanced expression of EZH2 gene stimulates proliferation and invasion of EOC cells, and regulates EOC microenvironment by promoting neoplastic angiogenesis [3, 4]. Depletion of EZH2, on the other hand, inhibits cell cycle
123
106
progression and triggers apoptosis in these cells [5]. EZH2 has been suggested as a putative target for developing EOC therapeutics, and identifying EZH2 target genes in EOC will allow, therefore, to gain insights into the etiology of the disease and to facilitate translational EOC research related to EZH2. The aplysia ras homolog member I (ARHI) is a maternally imprinted tumor-suppressor gene that encodes a 26-kDa small GTP-binding protein sharing about 60 % amino acid homology to Ras and Rap [6]. ARHI is expressed in normal ovarian epithelial cells but its expression is markedly down-regulated or even lost in the majority of EOC [7]. Recent reports show that ARHI plays a role of a negative regulator of EOC growth and progression [8]. Mechanisms of ARHI downregulation in cancer include loss of heterozygosity [7], transcriptional regulation, and decreased mRNA stability [9]. Studies show that downregulation of ARHI can also occur through epigenetic events such as aberrant methylation in the promoter region [10, 11], reduced histone H3 acetylation, and increased histone H3 methylation at lysine 9 [12, 13]. In the recent study, we provide the first evidence that ARHI is a novel target of repression by EZH2-mediated H3K27me3. We further show that depletion of ARHI partially reverses the growth inhibition induced by inactivation of EZH2 by 3-Deazaneplanocin A (DZNep). Collectively, our findings suggest that epigenetic silencing of ARHI is involved in the tumorigenic function of EZH2 in EOC.
Materials and Methods Reagents All reagents were purchased from Sigma-Aldrich unless specified otherwise. Cell Lines, Tissue Samples Normal ovarian epithelial cell line (IOSE29) and EOC cell lines (SKOV3, OVCA420, and OVCAR3) were obtained from the American Type Cell Culture Collection (ATCC, Manassas, VA, USA). The cells were maintained in RPMI1640 medium (Life Technologies) supplemented with 10 % FBS (Life Technologies) at 37 °C with 5 % CO2. A total of 75 tissue samples of primary EOCs and 12 samples of normal human ovarian tissues were obtained from the Department of Gynecology and Obstetrics at Provincial Hospital affiliated with Shandong University. The study was approved by Shandong University Ethics Committee and all patients provided written informed consent according to the committee’s regulations.
123
Cell Biochem Biophys (2015) 71:105–112
Immunohistochemical Staining EOC tissues were sectioned and mounted on polylysinecoated slides. The tissues were then dewaxed in xylene and rehydrated using a graded ethanol series. After three washes in phosphate-buffered saline, tissue sections were subjected to antigen retrieval by steaming in 0.01 mol/L of sodium citrate buffer (pH 6.0) for 30 min. After quenching endogenous peroxidase activity with 3 % hydrogen peroxide and blocking nonspecific protein binding with 1 % bovine serum albumin, sections were incubated overnight with primary monoclonal anti-EZH2 (Abcam; 1:100) or anti-ARHI (Abcam; 1:100) antibodies at 4 °C, followed by incubation with biotinylated goat anti-mouse IgG (Abcam, 1:400) for 1 h at 37 °C. Antibody complexes were detected with the labeled streptavidin–biotin system (DAKO), and visualized using chromogen 3,30-diaminobenzidine. Sections were lightly counterstained with hematoxylin and fixed with neutral balata for observation. EZH2 and ARHI staining scores were determined as a percentage of positive cells multiplied by the intensity of positive staining on the slide (0, no expression or no positive staining; 1, 1–10 % positive cells or light yellow; 2, 11–50 % positive cells or brownish yellow; 3, 51–75 % positive cells or dark brown, 4, [75 % positive cells). Cell Viability Assays Indirect counting of viable cells was determined by the tetrazolium salt MTT [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide] assay. Briefly, cells were plated onto 96-well culture plates at an optimal density of 5 9 104 cells/mL in 200 lL culture medium per well. After 24 or 48 h, 20 lL medium containing 5 mg/mL MTT was added to each well and incubated at 37 °C for 4 h. The medium was then gently aspirated, and 200 lL DMSO was added to each well to solubilize the formazan crystals. The optical density of each sample was then measured in a multi-well spectrophotometer at 490 nm. Six independent experiments were conducted. Real-Time RT-PCR Total RNA from ovarian tissues was extracted using TRIzol Reagent (Takara Bio Inc.) following manufacturer’s instructions, and first-strand cDNA was synthesized using two-step RT-PCR kit (Takara Bio Inc.). SYBR Green RT-PCR Kit (Takara Bio Inc.) was used for the real-time quantitative PCR reaction, and the results were analyzed with Roch-480 and Light Cycle 480SW 1.5 software. Total reaction volume of 20 lL included 4 lL of diluted cDNA, 10 lL SYBR Green PCR Master Mix, and 4 lM of forward and reverse primers. ARH1 was amplified using the
Cell Biochem Biophys (2015) 71:105–112
following oligonucleotides: F: 50 -TCTGCCCGCCCTGCT TAT-30 ; R: 50 -TTGCCGTCGCCACTCTTG-30 . b-actin was used as an internal control and amplified using the following primers: F: 50 -TGGCACCCAGCACAATGAA-30 R: 50 -CTAAGTCATAGTCCGCCTAGAAGCA-30 Western Blotting Cell proteins were extracted using lysis buffer containing 10 mmol/L Tris–HCl pH 7.4, 1 % Triton X-100 and protease/phosphatase inhibitors (Roche Diagnostics) and subjected to sodium dodecyl sulfate (SDS)-PAGE. Proteins were subsequently transferred to a PVDF membrane, blocked with 5 % bovine serum albumin, and incubated with anti-ARHI, H3K27me3 and H3K9me3 antibodies, and secondary HRP-conjugated antibody (Abcam). Blots were visualized using Amersham western blot detection reagent (GE Healthcare). Chromatin Immunoprecipitation (ChIP) SKOV3 cells were crosslinked with 1 % formaldehyde and quenched by adding 125 mM glycine. Cells were then washed and lysed with cell lysis buffer, consisting of 50 mM HEPES (pH 7.5), 1 mM EDTA (pH 8.0), 150 mM NaCl, 0.1 % sodium deoxycholate, 0.1 % SDS, 1 % Triton X-100, and complete PMSF. Next, chromatin was sheared to fragments of 300–500 bp by sonication. Lysates were pre-cleared with Salmon Sperm DNA/Protein A Agarose (Millipore) for 1–2 h. The following antibodies were used to perform ChIP: anti-H3K27me3 (Cell signaling) and antiEZH2 (Millipore). An isotype matched IgG was used as a negative control. Crosslinking of DNA fragments was reversed by pronase and subsequent incubation at 42 °C for 2 h and 68 °C for 8 h. The ARHI promoter DNA in the immunoprecipitates was detected by qPCR as described above using the following primers: 50 -TCGATTGTTGTAGATGCCAAG-30 50 -AGACTTACCTTTCTCGGAGGC-30 . shRNA, Lentivirus Packaging, and Infection The sense sequences of shRNA to the human EZH2 gene (shEZH2) and ARHI gene (shARHI) respectively are: shEZH2: 50 -GAAUGGAAACAGCGAAGGA-30 shARHI: 50 -GTGCTGTTGTTTGGACTGTAA-30 . Lentivirus packaging was performed using virapower system (Invitrogen) according to manufacturer’s instruction. OVCAR3 and SKOV3 at 50–60 % confluence were infected with lentivirus expressing shEZH2, shARHI, or vector only (control).
107
In Vitro Epigenetic Drugs Treatment DZNep (Cayman Chemical) was dissolved in dimethyl sulfoxide (DMSO). 5-Aza-dC was dissolved in 50 % acetic acid. TSA was dissolved in ethanol. Solvent only was used as a mock in the corresponding treatment. For DZNep treatment, DZNep (1 or 10 lM) was added to the cell culture medium for 48 or 72 h. For 5-Aza-dC treatment, 5-Aza-dC (10 lM) was replenished daily for 72 h. For TSA treatment, TSA (0.25 lg/mL) was only added to the cells in the last 24 h of the experiment. Statistical Analysis Quantitative data were expressed as mean ± SD. ANOVA or Student’s t test was used to identify significant differences in various groups. Differences in proportions were evaluated by the v2 test. The Spearman rank correlation analysis was used to analyze the correlation of EZH2 and ARHI expression. Overall survival was defined as the time elapsed from the date of diagnosis to the date of death from ovarian cancer. Kaplan–Meier survival plots were generated and comparisons made using the log-rank statistic. P \ 0.05 was considered to be statistically significant.
Results (1)
The expression of EZH2 inversely correlates with ARHI and predicts shorter overall survival in EOC patients.
Previous reports suggest that EZH2 is often overexpressed in EOCs. We evaluated the expressions of EZH2 in 75 EOC and 12 normal human ovarian tissue samples. Immunohistochemistry (IHC) analysis showed a significant upregulation of EZH2 in 64 % (48 out of 75) of EOC tissues as compared to normal ovarian tissues (P \ 0.01) (Fig. 1a). To evaluate the correlation between ARHI and EZH2 levels, we subsequently examined the expression levels of ARHI in the same set of EOC specimens. Higher levels of EZH2 expression coincided with decreased levels of ARH1 expression in the tumorous tissues (Fig. 1b, c; P \ 0.05). These results suggest that there is a significant inverse correlation between the expression of EZH2 and ARHI. We next assessed the connection between EZH2 expression and the prognosis of EOC patients (n = 55), for which longterm follow-up data were available. Increased expression of EZH2 coincided with the decreased survival rate (Fig. 1d; P \ 0.05), indicating a significant correlation between the expressions of EZH2 and overall survival in EOC patients.
123
108
Cell Biochem Biophys (2015) 71:105–112
Fig. 1 The expression of EZH2 inversely correlates with ARHI and predicts survival rates in EOC patients. a IHC analysis of normal human ovarian surface epithelium and human EOC tissues, stained with anti-EZH2 antibody and visualized at 9400 magnification. b IHC analysis of the expression levels of EZH2 and ARHI in different EOC tissues (EOC No.1 & No.2), magnification 9400.
c Correlation curve between expressions of EZH2 and ARHI in 38 EOC samples (P \ 0.05). d The univariate overall survival curve for EOC patients with high (n = 29) or low (n = 26) EZH2 expression, drown based on median levels of mRNA expression determined by qRT-PCR in a cohort of 55 EOC patients (P \ 0.05)
(2)
of shEZH2 in SKOV3 and OVCAR3 cells was confirmed by immunoblotting (Supplemental Fig. 1). Downregulation of EZH2 expression in EOC cells by shRNA coincided with the increase in ARHI mRNA (Fig. 2b) and protein levels (Fig. 2c). Since EZH2 mainly plays a suppressive role in gene expression through its methyltransferase activity at lysine 27 of histone H3 (H3K27me3), we examined the levels of H3K27me3 in shEZH2-expressing cells by Western blot analysis. EXH2 knock-down resulted in significantly reduced levels of H3K27me3, as compared to control cells. In contrast, there was no difference in the level of H3K9me3 (Fig. 2c). We next tested whether EZH2-mediated H3K27me3 directly regulates ARHI in EOC cells. Chromatin immunoprecipitation assay demonstrated direct binding of EZH2
EZH2 downregulates ARHI expression by promoting trimethylation on lysine 27 of histone H3 (H3K27me3).
To further study the correlation between the expression of ARHI and EZH2, we measured ARHI and EZH2 protein content in the normal ovarian epithelial cell line (IOSE29) and EOC cell lines, SKOV3 and OVCAR3. EZH2 was significantly over-expressed in both SKOV3 and OVCAR3 cells, as compared to IOSE29 cells. In contrast, ARHI levels were lower in SKOV3 and OVCAR3 cells, comparing to IOSE29 cells (Fig. 2a). To study the interaction between ARHI and EZH2, we knocked down EZH2 expression in EOC cells using shRNA and investigated whether ARHI expression could be restored upon depletion of EZH2. Knockdown efficacy
123
Cell Biochem Biophys (2015) 71:105–112
109
Fig. 2 EZH2 downregulates ARHI by catalyzing trimethylation on lysine 27 of histone H3 (H3K27me3). a Protein levels of EZH2 and ARHI were examined in IOSE29, SKOV3, and OVCAR3 cells by immunoblotting. b SKOV3 and OVCAR3 cells were infected with a lentiviral vector carrying shEZH2 or control vector. Expression of ARHI in the infected cells was determined by qRT-PCR. c Expression
of ARHI, H3K27me3, and H3K9me3 was analyzed by immunoblotting in the control and shEZH2-expressing cells. d SKOV3 cells were subjected to ChIP analysis using antibodies against H3K27me3 or EZH2 with primers targeted to the promoter region of ARHI. Isotype matched IgG was used as a negative control. Results are presented as mean ± SD from three independent experiments (*P \ 0.05)
to the promoter region of ARHI in SKOV3 cells. Likewise, H3K27me3 epigenetic mark was present in the ARHI genomic locus (Fig. 2d).Together these results suggest that ARHI may be a target gene of EZH2, and is down-regulated in EOC cells by mechanism involving H3K27me3.
evaluated by qPCR. The combined treatment of the three drugs synergistically restored ARHI expression in SKOV3 cells (7-fold increase comparing to untreated control) (Fig. 3a). However, the co-treatment in OVCA420 cells did not induce further increase in ARHI expression as compared to 5-Aza-dC alone (Fig. 3b), suggesting that DNA methylation is a predominant epigenetic mechanism for silencing ARHI in this cell line.
(3)
ARHI is synergistically silenced by DNA methylation and histone modification.
Since DNA methylation and post-translational modifications of histone proteins are intimately linked to generating a less permissive chromatin environment to suppress gene transcription, we sought to test whether ARHI expression in EOC is regulated through the combinational effect of different epigenetic machineries. Two EOC cell lines were selected: SCOV3 cells, in which ARHI promoter is only partially methylated, and OVCA420 cells with high degree of ARHI promoter methylation [10]. Both cell lines were treated with 3-Deazaneplanocin A (DZNep), a small molecule EZH2 inhibitor, as well as 5-Aza-20 deoxycytidine (5-Aza-dC) and Trichostatin A (TSA), well characterized DNA methylation and histone acetylation inhibitors, respectively. ARHI mRNA expression was subsequently
(4)
DZNep treatment decreases survival of EOC cells by restoring ARHI expression. Our results suggest that EZH2 is involved in suppressing ARHI in EOC cells. We further tested whether inhibiting EZH2 could decrease EOC cell survival through restoring the expression of ARHI. Inhibiting EZH2 in SKOV3 cells by treating them with DZNep resulted in significantly elevated protein levels of ARHI (Fig. 4a) that coincided with significantly decreased cell survival rates (Fig. 4b). At the same time, depleting ARHI expression in SKOV3 cells by shRNA restored cell survival rates to the level of untreated cells (control), thus reversing the inhibitory effect of DZNep on EOC cell survival (Fig. 4b).
123
110
Cell Biochem Biophys (2015) 71:105–112
Fig. 3 ARHI is synergistically silenced by DNA methylation and histone modification. a SKOV3 cells were treated with 10 lM 5-AzadC, 0.25 lg/mL TSA and 10 lM DZNep. Expression of ARHI was subsequently determined by qRT-PCR. Results were normalized of b-actin, and are presented as mean ± SD from three independent
experiments (*P \ 0.05, **P \ 0.01). b OVCA420 cells were treated with 5-Aza-dC, TSA, and DZNep and analyzed as described in (a). Data are presented as mean ± SD from three independent experiments (*P \ 0.05, **P \ 0.01)
Fig. 4 DZNep treatment decreases survival of EOC cells by restoring ARHI expression. a SKOV3 cells were infected with a lentiviral vector encoding shARHI or control vector, and treated with DZNep or left untreated. Levels of EZH2 and ARHI were examined by immunoblotting. b Cell viability in control EOC cells, cells treated
with DZNep alone and ARHI knock-down cells (shARHI) treated with DZNep was measured by MTT assay. Results were normalized for control and are presented as mean ± SD from three independent experiments (*P \ 0.05)
Discussion
decreased expression of ARHI in epithelial ovarian cancers. EZH2 is a core catalytic subunit of Polycomb group proteins (PcGs), which catalyzes the trimethylation of histone H3 lysine27. As a significant epigenetic regulator, EZH2 is highly expressed in a wide range of human cancers and has been shown to mediate the expression of target genes involved in cell cycle progression, proliferation, differentiation, and neoplastic cell transformation [2]. We have demonstrated that EZH2 protein is overexpressed in over 60 % of EOC. We have shown a correlation between the levels of EZH2 expression and the survival rates of EOC patients: patients with EOC expressing high levels of EZH2 exhibited worse overall survival rates than the patients with EOC expressing low level of EZH2. EZH2, therefore, can be regarded as an independent prognostic biomarker in EOC.
The maternally imprinted growth regulatory gene ARHI is a tumor-suppressor gene whose expression is down-regulated or lost in 70 % of ovarian cancers and invasive breast cancers [10]. Due to imprinting of the maternal allele, loss of ARHI function can be achieved with a ‘single hit’ during carcinogenesis. Several mechanisms have been identified to regulate ARHI expression including loss of heterozygosity [7], transcriptional regulation, and decreased mRNA stability [9]. Additionally, downregulation of the paternal allele can also occur through epigenetic events such as aberrant methylation of the promoter CpG islands [10, 11], reduced histone H3 acetylation, and histone H3 lysine 9 methylation [12, 13]. In this study, we show that EZH2-mediated histone H3 lysine 27 methylation (H3K27me3) can also contribute to
123
Cell Biochem Biophys (2015) 71:105–112
Previous studies successfully used chromatin immunoprecipitation-on-chip analysis to identify a number of EZH2 target genes in EOC cells [14]. In this study, we have demonstrated that EZH2 directly binds to ARHI promoter region, suggesting that ARHI is a novel target of EZH2. We showed that EZH2-mediated gene silencing via H3K27me3. Upregulation of EZH2 clearly coincided with reduced cell survival, an effect that can be reversed by depleting EZH2 in EOC cells by shRNA. Since multiple epigenetic repressive machineries are intimately linked to ARHI suppression, we further demonstrated that ARHI was co-regulated by DNA methylation, histone deacetylation, and EZH2-mediated H3K27me3. However, the co-regulation of ARHI by these three epigenetic mechanisms was only observed when its major CpG islands were partially methylated. Once ARHI promoter was fully methylated (such as in OVCA420 cells), H3K27me3 was absent and DNA methylation was the main repressive mechanism, while histone deacetylation played only minimal role in ARHI suppression. This observation may reflect the crosstalk of EZH2 silencing and DNA methylation in an earlier stage of epigenetic repression of tumor-suppressor genes prior to the eventual replacement of H3K27me3 silencing by the stable DNA methylation machinery. Pharmacologic targeting of deregulated epigenetic proteins emerges as an attractive approach in cancer therapy. DZNep has been shown to eradicate tumor-initiating hepatocellular carcinoma cell in xenografted nude mice [15], induce apoptosis in breast cancer cells [16] and target acute myeloid leukemia when used in combination with panobinostat [17]. However, the suppressive effect of DZNep in EOC cells has yet to be evaluated. Our findings indicated that DZNep, to some extent, released the repression of ARHI expression by EZH2 and may, therefore, function as a potent inhibitor for EOC. A detailed pharmacological characterization of the ability of DZNep to suppress EOC growth and progression in vivo is still warranted to investigate the therapeutic potential of DZNep as EOC treatment regimen. In summary, the data reported here indicate that EZH2induced H3K27me3 is associated with epigenetic repression of ARHI tumor-suppressor gene in EOCs. Suppression of EZH2 by DZNep treatment could inhibit EOC cell survival through restoring the expression of ARHI. We propose, therefore, that EZH2 is widely involved in tumorigenesis at multiple levels and could be a potential target for EOC prevention and therapeutic intervention. Acknowledgments This study was supported by the National Natural Science Foundation of China (Grant No. is 81172482), the Science and Technology Department of Shandong Province (Grant No. is 2008BS03044), Natural Science Foundation of Shandong Province (Grant No. is ZR2013HQ060) and Postdoctoral Science Foundation of China (Grant No. is 2012M520201).
111
References 1. Rescigno, P., Cerillo, I., Ruocco, R., Condello, C., De Placido, S., & Pensabene, M. (2013). New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. BioMed Research International, 2013, 852839. 2. Chase, A., & Cross, N. C. (2011). Aberrations of EZH2 in cancer. Clinical Cancer Research, 17, 2613–2618. 3. Li, H., & Zhang, R. (2013). Role of EZH2 in epithelial ovarian cancer: from biological insights to therapeutic target. Frontiers in Oncology, 3, 47. 4. Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozbun, L., et al. (2010). Regulation of tumor angiogenesis by EZH2. Cancer Cell, 18, 185–197. 5. Seward, S., Semaan, A., Qazi, A. M., Gruzdyn, O. V., Chamala, S., Bryant, C. C., et al. (2013). EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating reexpression of p21(waf1/cip1) and by inhibiting mutant p53. Cancer Letters, 336, 53–60. 6. Peng, H., Xu, F., Pershad, R., Hunt, K. K., Frazier, M. L., Berchuck, A., et al. (2000). ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. International Journal of Cancer, 86, 690–694. 7. Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Li, Y., et al. (1999). NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 96, 214–219. 8. Lu, Z., Luo, R. Z., Lu, Y., Zhang, X., Yu, Q., Khare, S., et al. (2008). The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. The Journal of Clinical Investigation, 118, 3917–3929. 9. Lu, Z., Luo, R. Z., Peng, H., Rosen, D. G., Atkinson, E. N., Warneke, C., et al. (2006). Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clinical Cancer Research, 12, 2404–2413. 10. Feng, W., Marquez, R. T., Lu, Z., Liu, J., Lu, K. H., Issa, J. P., et al. (2008). Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer, 112, 1489–1502. 11. Yuan, J., Luo, R. Z., Fujii, S., Wang, L., Hu, W., Andreeff, M., et al. (2003). Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Research, 63, 4174–4180. 12. Fujii, S., Luo, R. Z., Yuan, J., Kadota, M., Oshimura, M., Dent, S. R., et al. (2003). Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Human Molecular Genetics, 12, 1791–1800. 13. Lu, Z., Luo, R. Z., Peng, H., Huang, M., Nishmoto, A., Hunt, K. K., et al. (2006). E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. Oncogene, 25, 230–239. 14. Li, H., Bitler, B. G., Vathipadiekal, V., Maradeo, M. E., Slifker, M., Creasy, C. L., et al. (2012). ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genomewide approaches. Cancer Prevention Research (Philadelphia, PA.), 5, 484–491. 15. Chiba, T., Suzuki, E., Negishi, M., Saraya, A., Miyagi, S., Konuma, T., et al. (2012). 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. International Journal of Cancer, 130, 2557–2567.
123
112 16. Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & Development, 21, 1050–1063. 17. Fiskus, W., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., et al. (2009). Combined epigenetic therapy with the
123
Cell Biochem Biophys (2015) 71:105–112 histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 114, 2733–2743.
ORIGINAL PAPER
EZH2-Induced H3K27me3 is Associated with Epigenetic Repression of the ARHI Tumor-Suppressor Gene in Ovarian Cancer Yibing Fu • Jing Chen • Bo Pang • Chunyan Li Jing Zhao • Keng Shen
•
Published online: 31 July 2014 Ó Springer Science+Business Media New York 2014
Abstract Epithelial ovarian cancer (EOC) is the second leading cause of death from gynecological malignancies worldwide. Enhancer of zeste homology 2 (EZH2), participating in gene expression silencing by trimethylating histone 3 lysine 27 (H3K27me3), is often up-regulated in EOC. ARHI, an imprinted tumor-suppressor gene, is markedly down-regulated or even undetectable in the majority of EOC. To explore the correlation between EZH2 and ARHI expression in EOC as well as the possible mechanism of EZH2–ARH1 interaction. We used immunohistochemical staining to evaluate the expression of EZH2 and ARHI in EOC and normal ovarian tissue specimens; western blotting, shRNA, and chromatin immunoprecipitation were used to study the expression correlation of EZH2 and ARHI in EOC and normal ovarian epithelial cells and to further explore the mechanism of EZH2 regulation of ARHI expression. Cell viability assay was used to evaluate the influence of these two genes on cell survival. (1) The expression of EZH2 inversely correlated with ARHI expression levels and Electronic Supplementary Material The online version of this article (doi:10.1007/s12013-014-0168-1) contains supplementary material, which is available to authorized users. Y. Fu K. Shen (&) Department of Gynecology and Obstetrics, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China e-mail: [email protected] Y. Fu J. Chen C. Li J. Zhao Department of Gynecology and Obstetrics, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China B. Pang Department of Neurosurgery, Qilu Hospital, Shandong University, 107# Wenhuaxi Rd, Jinan 250012, China
predicted shorter overall survival in EOC patients; (2) EZH2 promoted repression of ARHI by catalyzing trimethylation on H3K27; (3) ARHI was synergistically silenced by DNA methylation and histone modification; and (4) DZNep, an inhibitor of EZH2, significantly reduced survival rate of EOC cells by restoring ARHI expression. EZH2-00 induced H3K27me3 is associated with epigenetic repression of the ARHI tumor-suppressor gene in EOC. Suppression of EZH2 by DZNep, as a way of restoring the expression of ARHI, could be a potential treatment modality to EOC. Keywords EZH2 H3K27me3 Epigenetic repression of the ARHI tumor-suppressor gene
Introduction Epithelial ovarian cancer (EOC) is the seventh most common cancer in women and the second leading cause of death from gynecological malignancies worldwide [1]. There is an urgent need, therefore, for better understanding of the etiology of EOC in order to develop novel therapeutics for this disease. Enhancer of zeste homology 2 (EZH2) is an essential catalytic subunit of polycomb repressive complex 2 (PRC2), which silences gene expression by generating a methylated epigenetic mark at the lysine 27 residue of histone H3 (H3K27me3) [2]. Previous studies showed that EZH2 is often up-regulated in EOC and in ovarian cancer-associated stromal endothelial cells. Enhanced expression of EZH2 gene stimulates proliferation and invasion of EOC cells, and regulates EOC microenvironment by promoting neoplastic angiogenesis [3, 4]. Depletion of EZH2, on the other hand, inhibits cell cycle
123
106
progression and triggers apoptosis in these cells [5]. EZH2 has been suggested as a putative target for developing EOC therapeutics, and identifying EZH2 target genes in EOC will allow, therefore, to gain insights into the etiology of the disease and to facilitate translational EOC research related to EZH2. The aplysia ras homolog member I (ARHI) is a maternally imprinted tumor-suppressor gene that encodes a 26-kDa small GTP-binding protein sharing about 60 % amino acid homology to Ras and Rap [6]. ARHI is expressed in normal ovarian epithelial cells but its expression is markedly down-regulated or even lost in the majority of EOC [7]. Recent reports show that ARHI plays a role of a negative regulator of EOC growth and progression [8]. Mechanisms of ARHI downregulation in cancer include loss of heterozygosity [7], transcriptional regulation, and decreased mRNA stability [9]. Studies show that downregulation of ARHI can also occur through epigenetic events such as aberrant methylation in the promoter region [10, 11], reduced histone H3 acetylation, and increased histone H3 methylation at lysine 9 [12, 13]. In the recent study, we provide the first evidence that ARHI is a novel target of repression by EZH2-mediated H3K27me3. We further show that depletion of ARHI partially reverses the growth inhibition induced by inactivation of EZH2 by 3-Deazaneplanocin A (DZNep). Collectively, our findings suggest that epigenetic silencing of ARHI is involved in the tumorigenic function of EZH2 in EOC.
Materials and Methods Reagents All reagents were purchased from Sigma-Aldrich unless specified otherwise. Cell Lines, Tissue Samples Normal ovarian epithelial cell line (IOSE29) and EOC cell lines (SKOV3, OVCA420, and OVCAR3) were obtained from the American Type Cell Culture Collection (ATCC, Manassas, VA, USA). The cells were maintained in RPMI1640 medium (Life Technologies) supplemented with 10 % FBS (Life Technologies) at 37 °C with 5 % CO2. A total of 75 tissue samples of primary EOCs and 12 samples of normal human ovarian tissues were obtained from the Department of Gynecology and Obstetrics at Provincial Hospital affiliated with Shandong University. The study was approved by Shandong University Ethics Committee and all patients provided written informed consent according to the committee’s regulations.
123
Cell Biochem Biophys (2015) 71:105–112
Immunohistochemical Staining EOC tissues were sectioned and mounted on polylysinecoated slides. The tissues were then dewaxed in xylene and rehydrated using a graded ethanol series. After three washes in phosphate-buffered saline, tissue sections were subjected to antigen retrieval by steaming in 0.01 mol/L of sodium citrate buffer (pH 6.0) for 30 min. After quenching endogenous peroxidase activity with 3 % hydrogen peroxide and blocking nonspecific protein binding with 1 % bovine serum albumin, sections were incubated overnight with primary monoclonal anti-EZH2 (Abcam; 1:100) or anti-ARHI (Abcam; 1:100) antibodies at 4 °C, followed by incubation with biotinylated goat anti-mouse IgG (Abcam, 1:400) for 1 h at 37 °C. Antibody complexes were detected with the labeled streptavidin–biotin system (DAKO), and visualized using chromogen 3,30-diaminobenzidine. Sections were lightly counterstained with hematoxylin and fixed with neutral balata for observation. EZH2 and ARHI staining scores were determined as a percentage of positive cells multiplied by the intensity of positive staining on the slide (0, no expression or no positive staining; 1, 1–10 % positive cells or light yellow; 2, 11–50 % positive cells or brownish yellow; 3, 51–75 % positive cells or dark brown, 4, [75 % positive cells). Cell Viability Assays Indirect counting of viable cells was determined by the tetrazolium salt MTT [3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide] assay. Briefly, cells were plated onto 96-well culture plates at an optimal density of 5 9 104 cells/mL in 200 lL culture medium per well. After 24 or 48 h, 20 lL medium containing 5 mg/mL MTT was added to each well and incubated at 37 °C for 4 h. The medium was then gently aspirated, and 200 lL DMSO was added to each well to solubilize the formazan crystals. The optical density of each sample was then measured in a multi-well spectrophotometer at 490 nm. Six independent experiments were conducted. Real-Time RT-PCR Total RNA from ovarian tissues was extracted using TRIzol Reagent (Takara Bio Inc.) following manufacturer’s instructions, and first-strand cDNA was synthesized using two-step RT-PCR kit (Takara Bio Inc.). SYBR Green RT-PCR Kit (Takara Bio Inc.) was used for the real-time quantitative PCR reaction, and the results were analyzed with Roch-480 and Light Cycle 480SW 1.5 software. Total reaction volume of 20 lL included 4 lL of diluted cDNA, 10 lL SYBR Green PCR Master Mix, and 4 lM of forward and reverse primers. ARH1 was amplified using the
Cell Biochem Biophys (2015) 71:105–112
following oligonucleotides: F: 50 -TCTGCCCGCCCTGCT TAT-30 ; R: 50 -TTGCCGTCGCCACTCTTG-30 . b-actin was used as an internal control and amplified using the following primers: F: 50 -TGGCACCCAGCACAATGAA-30 R: 50 -CTAAGTCATAGTCCGCCTAGAAGCA-30 Western Blotting Cell proteins were extracted using lysis buffer containing 10 mmol/L Tris–HCl pH 7.4, 1 % Triton X-100 and protease/phosphatase inhibitors (Roche Diagnostics) and subjected to sodium dodecyl sulfate (SDS)-PAGE. Proteins were subsequently transferred to a PVDF membrane, blocked with 5 % bovine serum albumin, and incubated with anti-ARHI, H3K27me3 and H3K9me3 antibodies, and secondary HRP-conjugated antibody (Abcam). Blots were visualized using Amersham western blot detection reagent (GE Healthcare). Chromatin Immunoprecipitation (ChIP) SKOV3 cells were crosslinked with 1 % formaldehyde and quenched by adding 125 mM glycine. Cells were then washed and lysed with cell lysis buffer, consisting of 50 mM HEPES (pH 7.5), 1 mM EDTA (pH 8.0), 150 mM NaCl, 0.1 % sodium deoxycholate, 0.1 % SDS, 1 % Triton X-100, and complete PMSF. Next, chromatin was sheared to fragments of 300–500 bp by sonication. Lysates were pre-cleared with Salmon Sperm DNA/Protein A Agarose (Millipore) for 1–2 h. The following antibodies were used to perform ChIP: anti-H3K27me3 (Cell signaling) and antiEZH2 (Millipore). An isotype matched IgG was used as a negative control. Crosslinking of DNA fragments was reversed by pronase and subsequent incubation at 42 °C for 2 h and 68 °C for 8 h. The ARHI promoter DNA in the immunoprecipitates was detected by qPCR as described above using the following primers: 50 -TCGATTGTTGTAGATGCCAAG-30 50 -AGACTTACCTTTCTCGGAGGC-30 . shRNA, Lentivirus Packaging, and Infection The sense sequences of shRNA to the human EZH2 gene (shEZH2) and ARHI gene (shARHI) respectively are: shEZH2: 50 -GAAUGGAAACAGCGAAGGA-30 shARHI: 50 -GTGCTGTTGTTTGGACTGTAA-30 . Lentivirus packaging was performed using virapower system (Invitrogen) according to manufacturer’s instruction. OVCAR3 and SKOV3 at 50–60 % confluence were infected with lentivirus expressing shEZH2, shARHI, or vector only (control).
107
In Vitro Epigenetic Drugs Treatment DZNep (Cayman Chemical) was dissolved in dimethyl sulfoxide (DMSO). 5-Aza-dC was dissolved in 50 % acetic acid. TSA was dissolved in ethanol. Solvent only was used as a mock in the corresponding treatment. For DZNep treatment, DZNep (1 or 10 lM) was added to the cell culture medium for 48 or 72 h. For 5-Aza-dC treatment, 5-Aza-dC (10 lM) was replenished daily for 72 h. For TSA treatment, TSA (0.25 lg/mL) was only added to the cells in the last 24 h of the experiment. Statistical Analysis Quantitative data were expressed as mean ± SD. ANOVA or Student’s t test was used to identify significant differences in various groups. Differences in proportions were evaluated by the v2 test. The Spearman rank correlation analysis was used to analyze the correlation of EZH2 and ARHI expression. Overall survival was defined as the time elapsed from the date of diagnosis to the date of death from ovarian cancer. Kaplan–Meier survival plots were generated and comparisons made using the log-rank statistic. P \ 0.05 was considered to be statistically significant.
Results (1)
The expression of EZH2 inversely correlates with ARHI and predicts shorter overall survival in EOC patients.
Previous reports suggest that EZH2 is often overexpressed in EOCs. We evaluated the expressions of EZH2 in 75 EOC and 12 normal human ovarian tissue samples. Immunohistochemistry (IHC) analysis showed a significant upregulation of EZH2 in 64 % (48 out of 75) of EOC tissues as compared to normal ovarian tissues (P \ 0.01) (Fig. 1a). To evaluate the correlation between ARHI and EZH2 levels, we subsequently examined the expression levels of ARHI in the same set of EOC specimens. Higher levels of EZH2 expression coincided with decreased levels of ARH1 expression in the tumorous tissues (Fig. 1b, c; P \ 0.05). These results suggest that there is a significant inverse correlation between the expression of EZH2 and ARHI. We next assessed the connection between EZH2 expression and the prognosis of EOC patients (n = 55), for which longterm follow-up data were available. Increased expression of EZH2 coincided with the decreased survival rate (Fig. 1d; P \ 0.05), indicating a significant correlation between the expressions of EZH2 and overall survival in EOC patients.
123
108
Cell Biochem Biophys (2015) 71:105–112
Fig. 1 The expression of EZH2 inversely correlates with ARHI and predicts survival rates in EOC patients. a IHC analysis of normal human ovarian surface epithelium and human EOC tissues, stained with anti-EZH2 antibody and visualized at 9400 magnification. b IHC analysis of the expression levels of EZH2 and ARHI in different EOC tissues (EOC No.1 & No.2), magnification 9400.
c Correlation curve between expressions of EZH2 and ARHI in 38 EOC samples (P \ 0.05). d The univariate overall survival curve for EOC patients with high (n = 29) or low (n = 26) EZH2 expression, drown based on median levels of mRNA expression determined by qRT-PCR in a cohort of 55 EOC patients (P \ 0.05)
(2)
of shEZH2 in SKOV3 and OVCAR3 cells was confirmed by immunoblotting (Supplemental Fig. 1). Downregulation of EZH2 expression in EOC cells by shRNA coincided with the increase in ARHI mRNA (Fig. 2b) and protein levels (Fig. 2c). Since EZH2 mainly plays a suppressive role in gene expression through its methyltransferase activity at lysine 27 of histone H3 (H3K27me3), we examined the levels of H3K27me3 in shEZH2-expressing cells by Western blot analysis. EXH2 knock-down resulted in significantly reduced levels of H3K27me3, as compared to control cells. In contrast, there was no difference in the level of H3K9me3 (Fig. 2c). We next tested whether EZH2-mediated H3K27me3 directly regulates ARHI in EOC cells. Chromatin immunoprecipitation assay demonstrated direct binding of EZH2
EZH2 downregulates ARHI expression by promoting trimethylation on lysine 27 of histone H3 (H3K27me3).
To further study the correlation between the expression of ARHI and EZH2, we measured ARHI and EZH2 protein content in the normal ovarian epithelial cell line (IOSE29) and EOC cell lines, SKOV3 and OVCAR3. EZH2 was significantly over-expressed in both SKOV3 and OVCAR3 cells, as compared to IOSE29 cells. In contrast, ARHI levels were lower in SKOV3 and OVCAR3 cells, comparing to IOSE29 cells (Fig. 2a). To study the interaction between ARHI and EZH2, we knocked down EZH2 expression in EOC cells using shRNA and investigated whether ARHI expression could be restored upon depletion of EZH2. Knockdown efficacy
123
Cell Biochem Biophys (2015) 71:105–112
109
Fig. 2 EZH2 downregulates ARHI by catalyzing trimethylation on lysine 27 of histone H3 (H3K27me3). a Protein levels of EZH2 and ARHI were examined in IOSE29, SKOV3, and OVCAR3 cells by immunoblotting. b SKOV3 and OVCAR3 cells were infected with a lentiviral vector carrying shEZH2 or control vector. Expression of ARHI in the infected cells was determined by qRT-PCR. c Expression
of ARHI, H3K27me3, and H3K9me3 was analyzed by immunoblotting in the control and shEZH2-expressing cells. d SKOV3 cells were subjected to ChIP analysis using antibodies against H3K27me3 or EZH2 with primers targeted to the promoter region of ARHI. Isotype matched IgG was used as a negative control. Results are presented as mean ± SD from three independent experiments (*P \ 0.05)
to the promoter region of ARHI in SKOV3 cells. Likewise, H3K27me3 epigenetic mark was present in the ARHI genomic locus (Fig. 2d).Together these results suggest that ARHI may be a target gene of EZH2, and is down-regulated in EOC cells by mechanism involving H3K27me3.
evaluated by qPCR. The combined treatment of the three drugs synergistically restored ARHI expression in SKOV3 cells (7-fold increase comparing to untreated control) (Fig. 3a). However, the co-treatment in OVCA420 cells did not induce further increase in ARHI expression as compared to 5-Aza-dC alone (Fig. 3b), suggesting that DNA methylation is a predominant epigenetic mechanism for silencing ARHI in this cell line.
(3)
ARHI is synergistically silenced by DNA methylation and histone modification.
Since DNA methylation and post-translational modifications of histone proteins are intimately linked to generating a less permissive chromatin environment to suppress gene transcription, we sought to test whether ARHI expression in EOC is regulated through the combinational effect of different epigenetic machineries. Two EOC cell lines were selected: SCOV3 cells, in which ARHI promoter is only partially methylated, and OVCA420 cells with high degree of ARHI promoter methylation [10]. Both cell lines were treated with 3-Deazaneplanocin A (DZNep), a small molecule EZH2 inhibitor, as well as 5-Aza-20 deoxycytidine (5-Aza-dC) and Trichostatin A (TSA), well characterized DNA methylation and histone acetylation inhibitors, respectively. ARHI mRNA expression was subsequently
(4)
DZNep treatment decreases survival of EOC cells by restoring ARHI expression. Our results suggest that EZH2 is involved in suppressing ARHI in EOC cells. We further tested whether inhibiting EZH2 could decrease EOC cell survival through restoring the expression of ARHI. Inhibiting EZH2 in SKOV3 cells by treating them with DZNep resulted in significantly elevated protein levels of ARHI (Fig. 4a) that coincided with significantly decreased cell survival rates (Fig. 4b). At the same time, depleting ARHI expression in SKOV3 cells by shRNA restored cell survival rates to the level of untreated cells (control), thus reversing the inhibitory effect of DZNep on EOC cell survival (Fig. 4b).
123
110
Cell Biochem Biophys (2015) 71:105–112
Fig. 3 ARHI is synergistically silenced by DNA methylation and histone modification. a SKOV3 cells were treated with 10 lM 5-AzadC, 0.25 lg/mL TSA and 10 lM DZNep. Expression of ARHI was subsequently determined by qRT-PCR. Results were normalized of b-actin, and are presented as mean ± SD from three independent
experiments (*P \ 0.05, **P \ 0.01). b OVCA420 cells were treated with 5-Aza-dC, TSA, and DZNep and analyzed as described in (a). Data are presented as mean ± SD from three independent experiments (*P \ 0.05, **P \ 0.01)
Fig. 4 DZNep treatment decreases survival of EOC cells by restoring ARHI expression. a SKOV3 cells were infected with a lentiviral vector encoding shARHI or control vector, and treated with DZNep or left untreated. Levels of EZH2 and ARHI were examined by immunoblotting. b Cell viability in control EOC cells, cells treated
with DZNep alone and ARHI knock-down cells (shARHI) treated with DZNep was measured by MTT assay. Results were normalized for control and are presented as mean ± SD from three independent experiments (*P \ 0.05)
Discussion
decreased expression of ARHI in epithelial ovarian cancers. EZH2 is a core catalytic subunit of Polycomb group proteins (PcGs), which catalyzes the trimethylation of histone H3 lysine27. As a significant epigenetic regulator, EZH2 is highly expressed in a wide range of human cancers and has been shown to mediate the expression of target genes involved in cell cycle progression, proliferation, differentiation, and neoplastic cell transformation [2]. We have demonstrated that EZH2 protein is overexpressed in over 60 % of EOC. We have shown a correlation between the levels of EZH2 expression and the survival rates of EOC patients: patients with EOC expressing high levels of EZH2 exhibited worse overall survival rates than the patients with EOC expressing low level of EZH2. EZH2, therefore, can be regarded as an independent prognostic biomarker in EOC.
The maternally imprinted growth regulatory gene ARHI is a tumor-suppressor gene whose expression is down-regulated or lost in 70 % of ovarian cancers and invasive breast cancers [10]. Due to imprinting of the maternal allele, loss of ARHI function can be achieved with a ‘single hit’ during carcinogenesis. Several mechanisms have been identified to regulate ARHI expression including loss of heterozygosity [7], transcriptional regulation, and decreased mRNA stability [9]. Additionally, downregulation of the paternal allele can also occur through epigenetic events such as aberrant methylation of the promoter CpG islands [10, 11], reduced histone H3 acetylation, and histone H3 lysine 9 methylation [12, 13]. In this study, we show that EZH2-mediated histone H3 lysine 27 methylation (H3K27me3) can also contribute to
123
Cell Biochem Biophys (2015) 71:105–112
Previous studies successfully used chromatin immunoprecipitation-on-chip analysis to identify a number of EZH2 target genes in EOC cells [14]. In this study, we have demonstrated that EZH2 directly binds to ARHI promoter region, suggesting that ARHI is a novel target of EZH2. We showed that EZH2-mediated gene silencing via H3K27me3. Upregulation of EZH2 clearly coincided with reduced cell survival, an effect that can be reversed by depleting EZH2 in EOC cells by shRNA. Since multiple epigenetic repressive machineries are intimately linked to ARHI suppression, we further demonstrated that ARHI was co-regulated by DNA methylation, histone deacetylation, and EZH2-mediated H3K27me3. However, the co-regulation of ARHI by these three epigenetic mechanisms was only observed when its major CpG islands were partially methylated. Once ARHI promoter was fully methylated (such as in OVCA420 cells), H3K27me3 was absent and DNA methylation was the main repressive mechanism, while histone deacetylation played only minimal role in ARHI suppression. This observation may reflect the crosstalk of EZH2 silencing and DNA methylation in an earlier stage of epigenetic repression of tumor-suppressor genes prior to the eventual replacement of H3K27me3 silencing by the stable DNA methylation machinery. Pharmacologic targeting of deregulated epigenetic proteins emerges as an attractive approach in cancer therapy. DZNep has been shown to eradicate tumor-initiating hepatocellular carcinoma cell in xenografted nude mice [15], induce apoptosis in breast cancer cells [16] and target acute myeloid leukemia when used in combination with panobinostat [17]. However, the suppressive effect of DZNep in EOC cells has yet to be evaluated. Our findings indicated that DZNep, to some extent, released the repression of ARHI expression by EZH2 and may, therefore, function as a potent inhibitor for EOC. A detailed pharmacological characterization of the ability of DZNep to suppress EOC growth and progression in vivo is still warranted to investigate the therapeutic potential of DZNep as EOC treatment regimen. In summary, the data reported here indicate that EZH2induced H3K27me3 is associated with epigenetic repression of ARHI tumor-suppressor gene in EOCs. Suppression of EZH2 by DZNep treatment could inhibit EOC cell survival through restoring the expression of ARHI. We propose, therefore, that EZH2 is widely involved in tumorigenesis at multiple levels and could be a potential target for EOC prevention and therapeutic intervention. Acknowledgments This study was supported by the National Natural Science Foundation of China (Grant No. is 81172482), the Science and Technology Department of Shandong Province (Grant No. is 2008BS03044), Natural Science Foundation of Shandong Province (Grant No. is ZR2013HQ060) and Postdoctoral Science Foundation of China (Grant No. is 2012M520201).
111
References 1. Rescigno, P., Cerillo, I., Ruocco, R., Condello, C., De Placido, S., & Pensabene, M. (2013). New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. BioMed Research International, 2013, 852839. 2. Chase, A., & Cross, N. C. (2011). Aberrations of EZH2 in cancer. Clinical Cancer Research, 17, 2613–2618. 3. Li, H., & Zhang, R. (2013). Role of EZH2 in epithelial ovarian cancer: from biological insights to therapeutic target. Frontiers in Oncology, 3, 47. 4. Lu, C., Han, H. D., Mangala, L. S., Ali-Fehmi, R., Newton, C. S., Ozbun, L., et al. (2010). Regulation of tumor angiogenesis by EZH2. Cancer Cell, 18, 185–197. 5. Seward, S., Semaan, A., Qazi, A. M., Gruzdyn, O. V., Chamala, S., Bryant, C. C., et al. (2013). EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating reexpression of p21(waf1/cip1) and by inhibiting mutant p53. Cancer Letters, 336, 53–60. 6. Peng, H., Xu, F., Pershad, R., Hunt, K. K., Frazier, M. L., Berchuck, A., et al. (2000). ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. International Journal of Cancer, 86, 690–694. 7. Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Li, Y., et al. (1999). NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 96, 214–219. 8. Lu, Z., Luo, R. Z., Lu, Y., Zhang, X., Yu, Q., Khare, S., et al. (2008). The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. The Journal of Clinical Investigation, 118, 3917–3929. 9. Lu, Z., Luo, R. Z., Peng, H., Rosen, D. G., Atkinson, E. N., Warneke, C., et al. (2006). Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clinical Cancer Research, 12, 2404–2413. 10. Feng, W., Marquez, R. T., Lu, Z., Liu, J., Lu, K. H., Issa, J. P., et al. (2008). Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer, 112, 1489–1502. 11. Yuan, J., Luo, R. Z., Fujii, S., Wang, L., Hu, W., Andreeff, M., et al. (2003). Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Research, 63, 4174–4180. 12. Fujii, S., Luo, R. Z., Yuan, J., Kadota, M., Oshimura, M., Dent, S. R., et al. (2003). Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Human Molecular Genetics, 12, 1791–1800. 13. Lu, Z., Luo, R. Z., Peng, H., Huang, M., Nishmoto, A., Hunt, K. K., et al. (2006). E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. Oncogene, 25, 230–239. 14. Li, H., Bitler, B. G., Vathipadiekal, V., Maradeo, M. E., Slifker, M., Creasy, C. L., et al. (2012). ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genomewide approaches. Cancer Prevention Research (Philadelphia, PA.), 5, 484–491. 15. Chiba, T., Suzuki, E., Negishi, M., Saraya, A., Miyagi, S., Konuma, T., et al. (2012). 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. International Journal of Cancer, 130, 2557–2567.
123
112 16. Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes & Development, 21, 1050–1063. 17. Fiskus, W., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., et al. (2009). Combined epigenetic therapy with the
123
Cell Biochem Biophys (2015) 71:105–112 histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood, 114, 2733–2743.
